Clinical trials: Adults With Neovascular Age-related Macular Degeneration
Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
- Trial name
- JADE (NCT07484074)
- Testing
- Faricimab, OLN324
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 164 people
- Sponsor
- Ollin Biosciences, Inc.
Neovascular Age-related Macular Degeneration
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina.
- Trial name
- NCT07007065
- Testing
- Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control
- Where
- 138 sites in United States, Austria and 15 more
- Volunteers
- 561 people
- Sponsor
- AbbVie
Non-exudative Age-related Macular Degeneration, Diabetic Retinopathy
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem cells from bone marrow into the eye as treatment for patients who are irreversibly blind from various retinal conditions.
- Conditions
- Non-exudative Age-related Macular Degeneration, Diabetic Retinopathy, Retina Vein Occlusion, Retinitis Pigmentosa
- Trial name
- NCT01736059
- Testing
- CD34+ bone marrow stem cells intravitreal
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Davis
Wet Age Related Macular Degeneration
Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with neovascular (wet) age-related macular degeneration (nAMD).
- Trial name
- MOJAVE (NCT07816315)
- Testing
- OLN324, Aflibercept
- Volunteers
- 500 people
- Sponsor
- Ollin Biosciences, Inc.
Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Trial name
- NCT06864988
- Testing
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 94 sites in United States, Canada
- Volunteers
- 480 people
- Sponsor
- 4D Molecular Therapeutics
Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion
Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy
This is a single-arm, multicenter study to evaluate clinical usability of a pre-filled syringe containing SCD411 in adult patients with neovascular Wet Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO)…
- Conditions
- Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy
- Trial name
- NCT07501052
- Testing
- SCD411 0.05mL (2mg)
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
Retinal Vasculitis
A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
This study will describe and estimate the incidence of RV events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea® 2mg) therapy in US clinical practice.
- Trial name
- NCT06769412
- Testing
- aflibercept 2 mg
- Where
- United States
- Volunteers
- 550,000 people
- Sponsor
- Regeneron Pharmaceuticals
Neovascular Age-Related Macular Degeneration (nAMD)
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
This Phase 3 study is evaluating the safety and efficacy of 4D-150 versus aflibercept in participants with neovascular age-related macular degeneration (nAMD).
- Trial name
- 4FRONT-2 (NCT07064759)
- Testing
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 126 sites in United States, Argentina and 15 more
- Volunteers
- 480 people
- Sponsor
- 4D Molecular Therapeutics
Neovascular Age-Related Macular Degeneration
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid…
- Trial name
- SWIFT (NCT04264819)
- Testing
- RTH258/Brolucizumab
- Where
- 51 sites in France
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
Researchers are looking for a better way to treat participants who have diabetic macular edema (DME) or neovascular age-related macular degeneration (nAMD). DME is a diabetes-related eye disorder.
- Trial name
- DEUTERON (NCT06591598)
- Testing
- Aflibercept (BAY86-5321, Eylea)
- Where
- 6 sites in Czechia, Hungary and 1 more
- Volunteers
- 51 people
- Sponsor
- Bayer
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular…
- Trial name
- ELARA (NCT06491914)
- Testing
- Aflibercept 8 mg
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 1,126 people
- Sponsor
- Regeneron Pharmaceuticals
Macular Degeneration
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
This is a 28 day study to evaluate the pharmacodynamic effect of pazopanib eye drops on the central retinal thickness of AMD patients
- Trial name
- NCT00612456
- Testing
- Pazopanib
- Where
- 27 sites in United States, Australia and 2 more
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Adults With Neovascular Age-related Macular Degeneration
This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B.
Oculgen has begun a study of an investigational drug called OCUL101 as a possible treatment for neovascular AMD. An investigational drug is one that has not been approved by regulatory agencies, such as the Food and Drug…
- Trial name
- STAT (NCT07520318)
- Testing
- bispecific anti-VEGF and anti-complement
- Volunteers
- 255 people
- Sponsor
- Shenzhen Oculgen Biomedical Technology Co., Ltd.
Neovascular Age Related Macular Degeneration
A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration
Neovascular age-related macular degeneration (nAMD) is characterized by the presence of choroidal neovascularization (CNV). Choroidal neovascularization consists of abnormal blood vessels originating from the choroid and can lead…
- Trial name
- OCTOPUS (NCT04239027)
- Testing
- RTH258/Brolucizumab
- Where
- 40 sites in France
- Volunteers
- 210 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
This is a Phase 1/Phase 2 multicenter study to evaluate the safety and efficacy of a one-time single-eye intravitreal dose of SAR402663 in participants with neovascular age-related macular degeneration.
- Trial name
- NCT06660667
- Testing
- SAR402663, Diluent
- Where
- 26 sites in United States, United Kingdom
- Volunteers
- 66 people
- Sponsor
- Sanofi
Neovascular (Wet) Age-Related Macular Degeneration
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment.
- Trial name
- NCT05197270
- Testing
- 4D-150 IVT, Aflibercept IVT
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 215 people
- Sponsor
- 4D Molecular Therapeutics
Wet Age-related Macular Degeneration
Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with neovascular (wet) age-related macular degeneration (nAMD).
- Trial name
- SAHARA (NCT07816289)
- Testing
- OLN324, Ranibizumab
- Volunteers
- 400 people
- Sponsor
- Ollin Biosciences, Inc.
Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD)
An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
The purpose of this research study is to observe the patient's clinical care and how EYLEA® HD is used as a treatment in real-world settings.
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Visual Impairment
- Trial name
- SPECTRUM-US (NCT06398080)
- Testing
- aflibercept 8 mg
- Sponsor
- Regeneron Pharmaceuticals